177Lu vipivotide tetraxtan vs. Observation in PSMA positive metastatic prostate patients

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC) (CAAA617D12302)

Disease Types: Prostate

Available at: Roanoke

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC) (CAAA617D12302)

For More information:

https://clinicaltrials.gov/study/NCT05939414?term=An%20International,%20Prospective,%20Open-label,%20Multi-center,%20Randomized%20Phase%20III%20Study%20comparing%20lutetium%20(177Lu)%20vipivotide%20tetraxetan%20versus%20Observation%20to%20delay%20castration%20or%20disease%20recurrence%20in%20adult%20male%20patients%20with%20prostate-specific%20membrane%20antigen%20(PSMA)%20positive%20Oligometastatic%20Prostate%20Cancer%20(OMPC)%20(CAAA617D12302)&rank=1